TrialInternational journal of hematology2026

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.

Koji Izutsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.